January 21, 2025 - 17:34

Motorists may be at risk of losing out on a staggering £30 billion in compensation following a recent intervention by Rachel Reeves. The move aims to shield banks from a surge in loan mis-selling claims, raising concerns among consumers who may have been affected by questionable car finance practices.
Reeves' decision has sparked a debate about the balance between protecting financial institutions and ensuring that consumers receive justice for potential mis-selling. Many motorists who secured car loans under misleading terms could have been eligible for significant compensation, but the new measures could complicate or even eliminate their chances of receiving redress.
Consumer advocates are voicing their concerns, arguing that this intervention may disproportionately favor banks at the expense of everyday drivers. As discussions continue, the implications for those seeking compensation remain uncertain, leaving many motorists anxious about their financial rights and options in the wake of this policy change.
May 7, 2026 - 02:52
Assessing TFS Financial (TFSL) Valuation After Second Quarter Earnings And Continued Growth In Net IncomeTFS Financial (TFSL) reported its second quarter results, posting net interest income of US$77.81 million and net income of US$23.25 million. The company also showed modest earnings per share...
May 6, 2026 - 19:46
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate ProgressRevolution Medicines has released its financial results for the first quarter of 2026, alongside a significant update on its clinical pipeline. The company announced that its drug candidate...
May 6, 2026 - 01:18
Crypto’s ‘decentralised finance’ sector hit by investor exodus after hacksDecentralized finance, once hailed as the revolutionary future of banking and trading, is now dealing with a serious crisis of confidence. Investors are pulling funds out at a notable rate, driven...
May 5, 2026 - 23:12
Neurocrine Biosciences Reports First-Quarter 2026 Financial ResultsNeurocrine Biosciences released its financial report for the first quarter of 2026, covering the period ending March 31. The company disclosed its revenue and earnings figures for the three-month...